Table 1.
Characteristics of patients received allogeneic umbilical cord blood transplantation for MDS between 2004 and 2013
| Variable | N (%) |
|---|---|
| Number of patients | 176 |
| Patient-related | |
| Age, median (range) | 56 (18–73) |
| Gender | |
| Male | 99 (56) |
| Female | 77 (44) |
| Karnofsky score | |
| 90–100% | 127 (72) |
| < 90% | 47 (27) |
| Missing | 2 (1) |
| Comorbitidy score (HCT-CI) | |
| 0 | 57 (32) |
| 1–2 | 48 (27) |
| ≥3 | 60 (34) |
| Not available before 2007 | 11 (6) |
| Recipient CMV status | |
| Negative | 58 (33) |
| Positive | 117 (66) |
| Not tested | 1 (<1) |
| Disease-related | |
| Secondary MDS | |
| No | 146 (83) |
| Yes | 25 (14) |
| Missing | 5 (3) |
| Pre-transplantation cytoreductive therapy | |
| Hypomethylating agent only | 87 (49) |
| Intensive chemotherapy only | 19 (11) |
| Hypomethylating agent & intensive chemotherapy | 24 (14) |
| None | 40 (23) |
| Missing | 6 (3) |
| Bone marrow myeloblasts prior to transplantation | |
| < 5% | 127 (73) |
| 5–10% | 23 (13) |
| > 10% | 13 (7) |
| Missing | 13 (7) |
| Blast in blood prior to transplant | |
| ≤3% | 121 (69) |
| > 3% | 12 (7) |
| Missing | 43 (24) |
| Platelet count prior to transplant | |
| ≤ 50 × 109/L | 68 (39) |
| > 50 × 109/L | 108 (61) |
| Cytogenetic risk prior to conditioning | |
| Good | 61 (35) |
| Intermediate | 34 (19) |
| Poor | 34 (19) |
| Very poor | 3 (2) |
| Monosomal Karyotype | 30 (17) |
| Not tested | 2 (1) |
| Missing/unable to classify | 12 (7) |
| IPSS-R prior to transplant | |
| Very low | 18 (10) |
| Low | 41 (23) |
| Intermediate | 33 (19) |
| High | 34 (19) |
| Very high | 22 (13) |
| Missing | 28 (16) |
| CIBMTR MDS transplantation risk score [23] | |
| Low | 20 (11) |
| Intermediate | 78 (44) |
| High | 42 (24) |
| Very high | 1 (<1) |
| Missing | 35 (20) |
| Time between diagnosis and transplant | |
| 0–3 months | 54 (31) |
| 3–6 months | 56 (32) |
| ≥ 6 months | 66 (38) |
| Transplant-related | |
| Number of cord blood units | |
| Single cord | 36 (20) |
| Double cord | 140 (80) |
| Cord blood HLA matching | |
| 3/6 | 4 (2) |
| 4/6 | 102 (58) |
| 5/6 | 53 (30) |
| 6/6 | 4 (2) |
| Missing | 13 (7) |
| CD34+ cell dose, median (range), × 105/kg | 2 (<1–73) |
| CD34+ cell doses | |
| 0–2 × 105/kg | 83 (47) |
| 2–4 × 105/kg | 51 (29) |
| 4–8 × 105/kg | 16 (9) |
| > 8 × 105/kg | 14 (8) |
| Missing | 12 (7) |
| Nucleated cell doses, median (range), × 107/kg | 4 (<1–29) |
| Nucleated cell doses | |
| 0–2 × 107/kg | 13 (7) |
| 2–4 × 107/kg | 74 (42) |
| 4–8 × 107/kg | 75 (43) |
| > 8 × 107/kg | 5 (3) |
| Missing | 9 (5) |
| Donor-recipient sex match (1st cord blood unit) | |
| Male-Male | 38 (22) |
| Male-Female | 33 (19) |
| Female-Male | 41 (23) |
| Female-Female | 33 (19) |
| Missing | 31 (18) |
| Donor-recipient sex match (2nd cord blood unit) | |
| Male-Male | 20 (11) |
| Male-Female | 19 (11) |
| Female-Male | 24 (14) |
| Female-Female | 15 (9) |
| NA | 36 (20) |
| Missing | 62 (35) |
| Year of transplantation | |
| 2004–2007 | 24 (14) |
| 2008–2009 | 62 (35) |
| 2010–2011 | 46 (26) |
| 2012–2013 | 44 (25) |
| Conditioning regimen | |
| Myeloablative | 61 (35) |
| RIC/NMA | 115 (65) |
| Serotherapy used in conditioning | |
| ATG alone | 76 (43) |
| alemtuzumab alone | 1 (<1) |
| No ATG or alemtuzumab | 99 (56) |
| GVHD prophylaxis | |
| Tacrolimus-based | 81 (46) |
| Cyclosporine-based | 83 (47) |
| Other(s) | 8 (5) |
| Missing | 4 (2) |
| Median follow-up of survivors (range), months | 37 (3–78) |
List of abbreviations: Hematopoietic cell transplantation comorbidity index (HCT-CI), cytomegalovirus (CMV), human leukocyte antigen (HLA), reduced intensity conditioning (RIC), non-myeloablative (NMA), graft-versus-host disease (GVHD)